Fresh Tracks Therapeutics (Fresh Tracks Therapeutics) Cash-to-Debt : No Debt ⁽¹⁾ (As of Dec. 2023)

View and export this data going back to 1993. Start your Free Trial

What is Fresh Tracks Therapeutics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Fresh Tracks Therapeutics's cash to debt ratio for the quarter that ended in Dec. 2023 was No Debt ⁽¹⁾.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Fresh Tracks Therapeutics could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Fresh Tracks Therapeutics's Cash-to-Debt or its related term are showing as below:

FRTX' s Cash-to-Debt Range Over the Past 10 Years
Min: 58.93 Med: No Debt Max: No Debt
Current: 572

During the past 13 years, Fresh Tracks Therapeutics's highest Cash to Debt Ratio was No Debt. The lowest was 58.93. And the median was No Debt.

FRTX's Cash-to-Debt is ranked better than
86.3% of 1540 companies
in the Biotechnology industry
Industry Median: 6.485 vs FRTX: 572.00

Fresh Tracks Therapeutics Cash-to-Debt Historical Data

The historical data trend for Fresh Tracks Therapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Fresh Tracks Therapeutics Cash-to-Debt Chart

Fresh Tracks Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

77.68

58.93

389.62

177.14

No Debt

Fresh Tracks Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															177.14	384.43	470.95	No Debt	No Debt

Competitive Comparison of Fresh Tracks Therapeutics's Cash-to-Debt

For the Biotechnology subindustry, Fresh Tracks Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Fresh Tracks Therapeutics's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fresh Tracks Therapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Fresh Tracks Therapeutics's Cash-to-Debt falls into.

Fresh Tracks Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Fresh Tracks Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Fresh Tracks Therapeutics had no debt ⁽¹⁾.

Fresh Tracks Therapeutics's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Fresh Tracks Therapeutics had no debt ⁽¹⁾.

Fresh Tracks Therapeutics (OTCPK:FRTX) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Fresh Tracks Therapeutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Fresh Tracks Therapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Fresh Tracks Therapeutics (Fresh Tracks Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fresh Tracks Therapeutics Inc (OTCPK:FRTX) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

5777 Central Avenue, Suite 102, Boulder, CO, USA, 80301

Website

https://www.frtx.com

Fresh Tracks Therapeutics Inc is a clinical-stage pharmaceutical company striving to transform patient lives through the development of innovative and differentiated prescription therapeutics.

Executives

Monica E. Luchi	officer: Chief Medical Officer	430 EAST 29TH STREET, SUITE 940, NEW YORK NY 10016
Reginald L Hardy	director, officer: CHAIRMAN OF THE BOARD
David R. Mcavoy	officer: General Counsel and CCO	C/O ENDOCYTE, INC., 3000 KENT AVENUE, SUITE A1-100, WEST LAFAYETTE IN 47906
Deepak Chadha	officer: Chief Research & Dev. Officer	5777 CENTRAL AVENUE, SUITE 102, BOULDER CO 80301
Vijay B Samant	director	10390 PACIFIC CENTER COURT, SAN DIEGO CA 92121
Jose Breton	officer: Chief Accounting Officer	5777 CENTRAL AVENUE, SUITE 102, BOULDER CO 80301
Robert Busard Brown	director, officer: Chief Executive Officer	5777 CENTRAL AVENUE, SUITE 102, BOULDER CO 80301
Andrew D Sklawer	officer: COO and Secretary	5777 CENTRAL AVENUE, SUITE 102, BOULDER CO 80301
Dennison T Veru	director	C/O PALIDADE CAPITAL, ONE BRIDGE PLAZA NORTH #695, FORT LEE NJ 07024
Marchio Albert N Ii	officer: Chief Financial Officer
Gary A Lyons	director	12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130
Sanjeev Ahuja	officer: Chief Medical Officer	121 3RD STREET NW, CARMEL IN 46032
Adam Scott Levy	officer: Chief Business Officer	C/O MIRAGEN THERAPEUTICS, INC., 6200 LOOKOUT ROAD, #100, BOULDER CO 80301
William Ju	director	5777 CENTRAL AVENUE, SUITE 102, BOULDER CO 80301
R Michael Carruthers	officer: Chief Financial Officer	3122 STERLING CIRCLE, SUITE 200, BOULDER CO 80301